Drug discovery matters.

Millions of people worldwide suffer from Alzheimer’s and related dementias, without hope of survival. But there is hope in drug discovery.

The ADDF is committed to pursuing the most promising research to find effective treatments that can be brought quickly to patients.

100% of your donation goes directly to Alzheimer’s drug research and related programs. With your help, we can and will understand, treat, prevent and conquer this disease.

With my deepest thanks,

Leonard A. Lauder  
Co-Chairman

For more information about the ADDF, please visit www.AlzDiscovery.org
Mission

The mission of the Alzheimer’s Drug Discovery Foundation (ADDF) is to rapidly accelerate the discovery of drugs to prevent, treat and cure Alzheimer’s disease, related dementias and cognitive aging.

Approach

Founded in 1998 by co-chairmen Leonard A. and Ronald S. Lauder of the Estée Lauder cosmetics family, the ADDF provides funding to leading scientists who are conducting the most promising, innovative Alzheimer’s drug research worldwide.

Our goal is to provide seed funding for early-stage drug research that may otherwise go unfunded. By supporting cutting edge, diverse, novel research projects around the globe, we increase the chance of finding a cure.

100% of your donation goes directly to Alzheimer’s drug research and related programs. All of the ADDF’s administrative and overhead costs are covered by a private foundation.

Many of the ADDF’s grants are structured as investments, providing a return that is reinvested in new drug research.

Impact

The ADDF has invested nearly $60 million to fund over 400 Alzheimer’s drug discovery programs and clinical trials in academic centers and biotechnology companies in 18 countries.
A Letter from Dr. Howard Fillit and Nancy Lynn

Thanks to your support and generosity, 2012 was a year of significant growth for the Alzheimer’s Drug Discovery Foundation:

- We raised $9.2 million for research towards finding a cure, funding 37 scientific grants worldwide. One hundred percent of your contributions went directly to fund Alzheimer’s drug discovery and related programs.

- The U.S. Food and Drug Administration (FDA) approved Amyvid™, the first diagnostic test for Alzheimer’s and other causes of cognitive decline. ADDF provided the critical seed funding needed to launch the test’s early development.

- The ADDF/Belfer ApoE Therapeutics Innovation Program funded 3 projects to develop new drugs targeting Apolipoprotein E — a significant genetic risk factor for Alzheimer’s.

- We funded 6 human clinical studies via our Program to Accelerate Clinical Trials (PACT), with special thanks to major support from Nancy and Mel Goodes, The Charles Evans Foundation and The W. Garfield Weston Foundation.

- The National Institutes of Health (NIH) announced a $7.9 million grant to Suzanne Craft, PhD, at the University of Washington for a five-year clinical trial to evaluate an insulin nasal spray in Alzheimer’s patients. ADDF provided the critical early support for Dr. Craft’s program leading to this extended study.

- We registered our first international affiliate, ADDF-Canada, to expand funding for promising clinical trials in Canada.

- We hosted 2 international scientific conferences and held several signature events across the country. Gala highlights included honoring Nancy Reagan and fashion designer Carolina Herrera at our Great Ladies Luncheon and Fashion Show in Washington, DC and hosting an inaugural Hope on the Horizon Chicago Dinner with a special performance by legendary singer and guitarist Glen Campbell and his family.

There has never been a greater need for the ADDF. We received over 400 requests for funding new drugs from academic scientists and biotechnology companies across the world in 2012, up almost 40% from 2011.

Thank you for your continued commitment — with your help, we can move quickly towards conquering this disease.
Promise Through Drugs

The ADDF is committed to investing in a diverse portfolio of research programs and strengthening our network of partnerships until we discover a cure.

The ADDF focuses its funding entirely on preclinical drug discovery research and early-stage clinical trials involving new drug targets that hold great promise but may not be far enough along in the drug development pipeline to receive financial support from the pharmaceutical industry, investors or other partners. The ADDF bridges this critical gap in funding between basic research and later stage drug development, enabling the scientific pursuit of many innovative and novel therapies that might otherwise go unexplored.

ADDF’s focus on drug discovery is unique.

Our Funding Model — Venture Philanthropy

The ADDF is a biomedical venture philanthropy. Most of our grants are structured as mission-related investments, providing a return that is reinvested in new drug research. From more than $14 million invested in biotechnology programs, $2.8 million has been returned to date and immediately reinvested in new drug research programs. Subsequent to the ADDF’s initial funding, our grantees have received commitments of over $2 billion in follow-on funding from government, pharmaceutical companies and venture capital firms to further advance their drug research.

100% of your donation goes directly to Alzheimer’s drug research and related programs.
Where We Fund

The ADDF supports the most promising and diverse research projects around the world.
The ADDF has granted nearly $60 million to fund over 400 Alzheimer’s drug discovery programs and clinical trials in academic centers and at biotechnology companies in 18 countries. Below, we highlight select programs, grouped by therapeutic category.

### Therapeutic Target

<table>
<thead>
<tr>
<th>Therapeutic Target</th>
<th>Preclinical</th>
<th>Clinical</th>
<th>FDA Approval</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Amyloid</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prana Biotechnology*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zapaq, Inc./Comentis*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tel Aviv University</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cognition Therapeutics*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Tau</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Simon Fraser University</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New York University</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yuma Therapeutics*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duke University</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Neuroprotection</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rockefeller University</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Emory University</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>University of California, San Diego</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PharmatrophiX*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>University of California, Irvine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Northwestern University</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Boston University</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AgeneBio*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ApoE &amp; Vascular</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>University of Toronto</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ReXceptor*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duke University</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weill Cornell</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Madera*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Energy Utilization</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Seattle Institute</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Imperial College London</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metabolic Solutions*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mayo Clinic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Early Detection &amp; Diagnosis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>University of Pennsylvania</td>
<td></td>
<td></td>
<td>Avid, LILLY</td>
</tr>
<tr>
<td>Ohio State University</td>
<td></td>
<td></td>
<td>Tau imaging agents</td>
</tr>
</tbody>
</table>

### ADDF Drugs in the Pipeline

<table>
<thead>
<tr>
<th>Program</th>
<th>Pre-ADDF Funding</th>
<th>ADDF Catalytic/Gap Funding</th>
<th>Follow-on Funding (funder/partner(s) noted)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prana Biotechnology*</td>
<td></td>
<td>Astellas</td>
<td>Bexarotene (co-funded by Bright Focus and Case Western)</td>
</tr>
<tr>
<td>Zapaq, Inc./Comentis*</td>
<td></td>
<td>Neurophage</td>
<td>Angiotensin Receptor Blockers</td>
</tr>
<tr>
<td>Tel Aviv University</td>
<td></td>
<td>PI</td>
<td>ApoE mimetic</td>
</tr>
<tr>
<td>Cognition Therapeutics*</td>
<td></td>
<td>PI</td>
<td>ApoE gene therapy</td>
</tr>
<tr>
<td>Simon Fraser University</td>
<td></td>
<td>Alectos, MERCK</td>
<td>ApoE3 mimetic</td>
</tr>
<tr>
<td>New York University</td>
<td></td>
<td>NIH</td>
<td>Cognosci</td>
</tr>
<tr>
<td>Yuma Therapeutics*</td>
<td></td>
<td>NIH</td>
<td>Ceregene</td>
</tr>
<tr>
<td>Duke University</td>
<td></td>
<td>NIH</td>
<td>Ribazole</td>
</tr>
<tr>
<td>Rockefeller University</td>
<td></td>
<td>NIH</td>
<td>Riluzole</td>
</tr>
<tr>
<td>Emory University</td>
<td></td>
<td>NIH</td>
<td>Atomoxetine (Strattera®)</td>
</tr>
<tr>
<td>University of California, San Diego</td>
<td></td>
<td>NIH</td>
<td>NGF mimetics</td>
</tr>
<tr>
<td>PharmatrophiX*</td>
<td></td>
<td>NIH</td>
<td>NPHpro Inhibitors</td>
</tr>
<tr>
<td>University of California, Irvine</td>
<td></td>
<td>NIH</td>
<td>Allogreganalone</td>
</tr>
<tr>
<td>Northwestern University</td>
<td></td>
<td>NIH</td>
<td>Neuroinflammation blockers</td>
</tr>
<tr>
<td>Boston University</td>
<td></td>
<td>NIH</td>
<td>Proteasome Activators</td>
</tr>
<tr>
<td>AgeneBio*</td>
<td></td>
<td>NIH</td>
<td>PI</td>
</tr>
<tr>
<td>University of Toronto</td>
<td></td>
<td>NIH</td>
<td>Liraglutide (co-funded by Alzheimer’s Society, UK; in-kind support from NovoNordisk and GE)</td>
</tr>
<tr>
<td>ReXceptor*</td>
<td></td>
<td>NIH</td>
<td>GABA 5 ligands</td>
</tr>
<tr>
<td>Duke University</td>
<td></td>
<td>NIH</td>
<td>ApoE gene therapy</td>
</tr>
<tr>
<td>Weill Cornell</td>
<td></td>
<td>NIH</td>
<td>ApoE mimetic</td>
</tr>
<tr>
<td>Madera*</td>
<td></td>
<td>NIH</td>
<td>ApoE gene therapy</td>
</tr>
<tr>
<td>Seattle Institute</td>
<td></td>
<td>NIH</td>
<td>Intranasal Insulin</td>
</tr>
<tr>
<td>Imperial College London</td>
<td></td>
<td>NIH</td>
<td>Liraglutide (co-funded by Alzheimer’s Society, UK; in-kind support from NovoNordisk and GE)</td>
</tr>
<tr>
<td>Metabolic Solutions*</td>
<td></td>
<td>NIH</td>
<td>Mitoglitazone</td>
</tr>
<tr>
<td>Mayo Clinic</td>
<td></td>
<td>NIH</td>
<td>ApoE inducers</td>
</tr>
</tbody>
</table>

* Biotechnology Companies  NIH = National Institutes of Health  PI = Private Investor
**Spotlight on Amyvid**

In 2012, the U.S. Food and Drug Administration (FDA) approved Amyvid™, the first diagnostic test for Alzheimer’s disease. The ADDF provided crucial seed funding for the research of Amyvid from 2000-2004. This successful technology is an important proof-of-concept for the ADDF model, showcasing how early financial support for high-risk projects can lead to and accelerate the development of innovative drugs and diagnostics in Alzheimer’s.

“ADDF’s research support and commitment has been critical to the development of amyloid imaging technology. These are important assets in both research and clinical settings to identify beta-amyloid plaques, a neuropathological feature of Alzheimer’s disease.

Thanks to amyloid imaging agents like Amyvid and other related biomarkers, the field can now attempt prevention trials of Alzheimer’s — trials conducted under large public-private partnerships — designed to test whether early detection and early intervention can actually prevent the onset of symptoms. We hope this area of research, enabled by early investment from the ADDF, provides answers for patients and their loved ones.”

— Daniel Skovronsky, MD, PhD
Founder and CEO, Avid Radiopharmaceuticals

For more information about the ADDF, please visit [www.AlzDiscovery.org](http://www.AlzDiscovery.org)
Select Current Programs and Partnerships

Preclinical Drug Discovery

The ADDF’s preclinical program funds research focused on translating the knowledge we have gained about the underlying causes of Alzheimer’s disease into drugs. In 2012, 60% of our funding went towards preclinical drug discovery.

Carmela R. Abraham, PhD
Boston University
School of Medicine
Boston, Massachusetts

Dr. Abraham and her team are developing compounds to increase Klotho expression, a “longevity” target, to prevent age-related cognitive decline and Alzheimer’s disease. Interestingly, the gene Klotho is named after the Greek goddess who spins the thread of life.

Biotechnology

The ADDF helps create new biotechnology companies and funds early stage biotechnology companies, with programs dedicated to Alzheimer’s disease drug discovery. To date, the ADDF has funded almost 60 biotechnology programs.

Lawrence Wennogle, PhD
Intra-Cellular Therapies, Inc.
New York, New York

Dr. Wennogle’s research aims to further test several drugs that inhibit the casein kinase I (CKI) protein, a protein involved in regulating sleep cycles and that could impact multiple aspects of the Alzheimer’s disease process.

Program to Accelerate Clinical Trials (PACT)

The ADDF’s PACT supports the testing of promising drugs for Alzheimer’s in humans, giving innovative programs the chance to generate important safety and “proof-of-concept” data. The ADDF has funded 29 clinical trials.

Olga Meulenbroek, PhD
Radboud University Medical Centre
Nijmegen, The Netherlands

Dr. Meulenbroek and her team are testing whether nilvadipine, a calcium channel blocker FDA approved for treating high blood pressure, can increase blood flow to the brain, improve blood pressure stability, and ultimately improve cognition in Alzheimer's patients.
The ADDF/Belfer ApoE Therapeutics Innovation Program

The ADDF and the Robert A. and Renée E. Belfer Family Foundation established the ADDF/Belfer ApoE Therapeutics Innovation Program to accelerate the development of novel therapeutics specifically designed to target apolipoprotein E (ApoE), the most significant genetic risk factor for late-onset Alzheimer’s. Eight projects have been funded through the program.

Mary Jo LaDu, PhD
University of Illinois at Chicago
Chicago, Illinois

Dr. LaDu’s research aims to understand exactly how bexarotene, a cancer drug entering human testing, boosts ApoE levels and clears amyloid-beta protein. Results from this study will allow scientists to create more effective and safe ApoE-targeted drugs.

ADDF-Canada

In 2012, the ADDF launched its first international affiliate, ADDF-Canada. ADDF-Canada will provide funding to Canadian academic institutions and medical centers engaged in drug discovery and clinical trials to advance the development of novel therapeutics and diagnostic tools for Alzheimer’s disease, related dementias and cognitive aging.

Sandra Black, MD, FRCP(C)
Sunnybrook Research Institute
University of Toronto
Toronto, Canada

Dr. Black and her team are conducting a clinical trial to determine whether medication already being used to treat hypertension has the ability to protect against brain degeneration in people with or at risk for developing Alzheimer’s.

Aging and Alzheimer’s Prevention Program

The mission of ADDF’s Aging and Alzheimer’s Prevention Program is to provide a credible independent scientific voice — for the public and the scientific community — that evaluates the evidence for pharmaceuticals, supplements and natural products that are claimed to prevent or delay cognitive aging and Alzheimer’s (e.g., fish oil, coffee, and many others).

“In today’s challenging funding environment for scientific research, the awards I received from the ADDF were just what I needed as I was beginning to transition from basic research to drug development.”

— Carmela R. Abraham, PhD

For more information about the ADDF, please visit www.AlzDiscovery.org
Special Events

To broaden awareness and raise critical funds for Alzheimer’s drug research, the ADF

Second Annual Great Ladies Luncheon and Fashion Show

The Ritz-Carlton | Washington, DC
May 2, 2012

Executive Chairs
Ronald Frasch
Leonard A. Lauder
Elise and Marc Lefkowitz

In partnership with Saks Fifth Avenue, the ADF’s second annual Great Ladies Luncheon and Fashion Show raised $270,000. Highlights included honoring former First Lady Nancy Reagan and a fashion presentation by designer Carolina Herrera.


Sixth Annual Connoisseur’s Dinner: To Live is to Think

Sotheby’s | New York, NY
April 26, 2012

Executive Chairs
Leonard A. Lauder
Nancy Corzine

The ADF’s sixth annual Connoisseur’s Dinner raised $1.5 million for scientific drug research for Alzheimer’s. Nancy and Mel Goodes were awarded the second annual Chairman’s Award, and Sotheby’s Chairman, Jamie Niven, conducted the annual “Fund a Scientist” live auction, raising a record $447,900 onsite.

Clockwise from top left: Nancy and Mel Goodes. Nancy Corzine. Liz and Randal Sandler.
hosted five major special events.

“My mother generously and selflessly gave her time and energy to the causes she believed in. When Alzheimer’s disease took her life, we searched for a long time to find the right organization to support in her memory. We found the ADDF and decided to do all that we can to ensure that future families do not have to endure the heartbreak of losing a loved one to this terrible disease.”

— Elise Gelman Lefkowitz

Aspen Dinner

Maroon Creek Club | Aspen, CO
August 1, 2012

Executive Chairs
Leonard Lauder
Alison and Buzz Zaino

The ADDF’s signature event in Aspen featured a keynote presentation by Dr. Fillit, remarks by filmmaker James Keach and actress Jane Seymour, and a special preview of Glen Campbell’s “Goodbye Tour” documentary. Campbell was diagnosed with Alzheimer’s in 2011.
**Inaugural Hope on the Horizon Chicago Dinner**

The Art Institute of Chicago | Chicago, IL
November 5, 2012

*Executive Chairs*
Leonard A. Lauder
Nancy and A. Steven Crown

The ADFD’s inaugural *Hope on the Horizon* Chicago Dinner, hosted by award-winning actress Jane Seymour, brought together 265 guests and raised nearly $1.5 million for Alzheimer’s drug discovery research. Legendary guitarist and singer Glen Campbell performed selections from his “Goodbye Tour.”

**3rd Annual Hope on the Horizon Fall Luncheon & Symposium**

Metropolitan Club | New York, NY
September 27, 2012

*Executive Chairs*
Leonard A. Lauder
Sir Evelyn and Lady Lynn Forester de Rothschild
Nancy and Mel Goodes

The ADFD’s third annual Fall Luncheon & Symposium brought together more than 265 guests and raised nearly $700,000 for Alzheimer’s drug discovery research. The second annual Charles Evans Award was presented to Christopher Johnson, son of former New York Giants running back Ron Johnson who was diagnosed with Alzheimer’s in 2008.
Conferences, Training and Resources

The ADDF’s scientific conferences promote the exchange of ideas, the sharing of research results, and the formation of strategic alliances to further drug development goals.

6th Drug Discovery for Neurodegeneration Conference: An Intensive Course on Translating Research into Drugs
New York, NY | February 12-14, 2012
The ADDF’s annual conference, planned in conjunction with the National Institutes of Health, attracted approximately 140 academic, industry and government scientists from around the world. Designed to advance the development of new drugs for neurodegenerative diseases, the conference educated scientists on the principles and practice of drug discovery.

13th International Conference on Alzheimer’s Drug Discovery
Jersey City, NJ | September 10-11, 2012
This global conference, designed to accelerate the development of innovative treatments, attracted approximately 140 key stakeholders from the pharmaceutical, biotechnology, government and academic communities. The ADDF’s funded investigators and top-level scientists in the field presented their current research and provided progress.

The ADDF also hosted or exhibited at several other conferences in collaboration with other scientific institutions.

ADDF ACCESS Program

Drug discovery is a team effort, requiring collaboration between scientists with many different types of experience, from biology to chemistry to pharmacology. To help scientists find access to the expertise they need, the ADDF established the ADDF ACCESS program in 2012. The program connects scientists with networks of collaborators, consultants, contract research organizations (CROs) and experimental tools. It provides Alzheimer’s scientists with educational materials on the drug discovery process and guidance and expertise on the process of selecting and managing CRO relationships. For more information about the ADDF ACCESS Program, visit http://www.alzdiscovery.org/research-and-grants/addf-access/.

For more information about the ADDF, please visit www.AlzDiscovery.org
Alzheimer’s is a progressive, fatal neurodegenerative disease and the most common cause of dementia. There are currently no drugs available that prevent or even slow its course, but scientists are making measurable progress towards finding treatments.

In 2012, an estimated 5.4 million Americans suffered from Alzheimer’s; by 2050, that number is expected to triple. With an aging population and increasing number of people with Alzheimer’s, it is critical we continue to invest in research and discover a cure.

*There is hope in drug discovery.* With your support, we can and will understand, prevent and conquer this disease.

Please give generously today at [www.AlzDiscovery.org](http://www.AlzDiscovery.org)

100% of your donation goes directly to Alzheimer’s drug research and related programs.
## 2012 Donors

### Over $1,000,000
- Anonymous
- The Robert A. and Renée E. Belfer Family Foundation
- The Charles Evans Foundation
  - Mrs. Bonnie Pfeiffer Evans, Co-Trustee
  - Mrs. Alice Shure, Co-Trustee
- Mr. and Mrs. Melvin R. Goodes
- Evelyn H. Lauder Charitable Trust
  - The W. Garfield Weston Foundation

### $100,000 to $999,999
- The Association for Frontotemporal Degeneration
- BrightFocus Foundation
- The Charles River Laboratories
- Ms. Nancy Corzine
- The Estée Lauder Companies Inc.
- Mr. and Mrs. Nathan Kirsh
- Mr. Leonard A. Lauder
- The Leonard and Evelyn Lauder Foundation
  - Mr. and Mrs. Marc Lefkowitz
- Lewy Body Dementia Association
- National Institutes of Health
  - Mr. and Mrs. Randal B. Sandler

### $50,000 to $99,999
- Anonymous
- Aetna Foundation
- Mr. and Mrs. David M. Baldwin
- The Bluhm Family Charitable Foundation
- Mr. and Mrs. A. Steven Crown
- Mr. and Mrs. James S. Crown
- Mr. and Mrs. Raymond Dalio
- Sir Evelyn and Lady Lynn Forester de Rothschild
- Leslie and Roslyn Goldstein Foundation
- Mr. and Mrs. Richard Goodman
- Mr. and Mrs. Jim Gordon, The Edgewater Funds
- Graff Diamonds
- Mr. and Mrs. Kenneth C. Griffin
- Ms. Dina Merrill Hartley and Mr. Ted Hartley
- Mrs. Bonnie Englehardt Lautenberg and Senator Frank Lautenberg
- The Lefkofsky Family Foundation
- Christy and John Mack Foundation
- Mr. and Mrs. Barry L. MacLean
- New York Academy of Sciences
  - Mr. and Mrs. J.B. Pritzker
- Mr. and Mrs. J. Christopher Reyes
- Mr. and Mrs. Andrew Rosenfield
- Mr. and Mrs. John W. Rowe
- Mr. and Mrs. Michael J. Sacks
- Mr. and Mrs. Gordon Segal
- Mr. and Mrs. Peter J. Solomon
- The Spiritus Gladius Foundation
- Tishman Speyer Properties, LP
  - Mr. and Mrs. Byron D. Trott

### $25,000 to $49,999
- Alzheimer's Foundation of America
- Mr. and Mrs. Jeffrey S. Aronin
- Bloomberg LP
- Ms. Carol Seabrook Boulanger
- Mr. and Mrs. John A. Cannig
- Mr. and Mrs. James Cohen
- Ms. Francie Comer
- Condé Nast
- Mr. and Mrs. Howard Draft
- Mr. and Mrs. Mitchell Eichen
  - Ernst & Young, LLP
- First Republic Bank
- The Samuel Freeman Charitable Trust
- Teaman and Grace Fuite Foundation
- Mr. Philip H. Geier, Jr.
- Mrs. Judy Glickman
- The Lauder Foundation
- Le Papillon Ltd. / Mr. Watson J. Warriner, Jr.
- Mr. and Mrs. Laurence C. Leeds, Jr.
- Lilly USA, LLC
- Mr. Philip Lovett
- Merck Research Laboratories
- The David A. and Mildred H. Morse Charitable Trust
- Northern Trust
- Mr. and Mrs. Thomas S. Ricketts
- Ms. Lois Robbins
- Mr. and Mrs. William C. Rudin
- Sotheby's
- Ms. Joan Sutton Straus
- Mr. and Mrs. Michael Weisman
  - World Events Forum, Inc.
- Mr. and Mrs. Buzz Zaino

### $10,000 to $24,999
- Abbott Laboratories
- Mr. and Mrs. Robert Baizer
- Baxter International Inc., Mr. Robert L. Parkinson, Jr.
- Mr. and Mrs. Philip J. Bazelides
- Mr. Howard Bernick
- Carol Lavin Bernick Family Foundation
- Mr. and Mrs. Daniel S. Bernstein
- Ms. Alecia Blake and Mr. Curtis Rudbart
- Mr. and Mrs. Robert S. Blank
- Bulley & Andrews, LLC
- Mr. Louis C. Camilleri
- Mr. and Mrs. Arthur Carter
- Mr. and Mrs. Marvin H. Davidson
- Mr. David Deckelbaum
- Mr. and Mrs. Charles M. Diker
- Elan Pharmaceuticals, Inc.
- Emory University
- Ms. Mary C. Farrell
- Frontenac Company, LLC
- Mr. Richard Gerson
- Mr. and Mrs. Henry Goldberg
- Mr. and Mrs. King W. Harris
- Ms. Marlene Hess and Mr. James D. Zirin
- Mr. Gregory Jones
- The Kameff Foundation
- Mr. and Mrs. Michael Katzke
- Mr. and Mrs. Howard Kessler
- Mr. and Mrs. Lester Knight
- Mr. Dan Lufkin, The Peter Jay Sharp Foundation
- Ms. Michelle MacDonald
- Mr. William E. Mayer
- Mr. Samuel M. Menoff
- Mr. and Mrs. William Miller
- Mr. and Mrs. Marc S. Moller
- Motorola Solutions, Inc.
- Pfizer Inc.
- Mr. Thomas Pheasant
- Mr. and Mrs. Michael Pierce
- PLVTZ GUC Trust, Mr. Jeffrey Cohen
- Mr. and Mrs. Robert Prince
- Ms. Lita Rosenberg
- Mr. and Mrs. Mortimer Sackler
- Ms. Sharon T. Sager and Mr. Loring Swasey, UBS Private Wealth
- Saks Fifth Avenue
- Mr. and Mrs. Nathan Sandler
- Mr. and Mrs. Paul C. Schorr Ill
- Anna and John J. Sie Foundation
- The Sun-Times Foundation
- Ms. Sally Susman, Pfizer Inc.
- Ms. Mary Rose Taylor
- Mr. and Mrs. Andrew Tisch

For more information about the ADHF, please visit www.AlzDiscovery.org
Mr. and Mrs. John L. Vogelstein
Ms. Giselle F. Wagner and
Mr. Paul A. Myerson
Nina W. Werblow Charitable Trust
Mr. and Mrs. Robert B. Zink

$5,000 to $9,999
Mr. and Mrs. James D. Abrams
The Anne and Ronald Abramson
Family Foundation
Ms. Deirdre Adkins
Aon Foundation
Mr. and Mrs. Robert Banks
Mr. and Mrs. Ron Baron, Baron Capital
Foundation
Mr. and Mrs. Gustavo A. Cisneros
Mr. Michael T. Cohen
Mr. Robert O. Delaney
Mr. and Mrs. Warren Diamond
Mr. and Mrs. Craig Duchossois
Mr. and Mrs. Paul Edgerley
Mr. and Mrs. Joel S. Ehrenkranz
Father's Day/Mother's Day Council, Inc.
Mr. and Mrs. George Ferris
Mr. and Ms. Dennis FitzSimons
Forest Laboratories, Inc.
Mr. and Mrs. Thomas Friedman
Mr. and Mrs. Richard I. Furman
The Gabelli Funds
The Giants Foundation, Inc.
GlaxoSmithKline
Mr. and Mrs. Roger Hertog
Janssen Research & Development-Johnson & Johnson
Mr. and Mrs. Harry P. Kamen
Kekst and Company Incorporated
Lazo Foundation
Mr. and Mrs. Daniel S. Loeb
Mrs. Holly Madigan
Ms. Barbara Manilow
The Marc Haas Foundation, Mr. and Mrs. Stanley Shuman
Mr. and Mrs. Kelly Martin
Ms. Carlyn McCaffrey
Mr. and Mrs. John McCambridge
Mr. and Mrs. Andrew McKenna
Michael J. Fox Foundation for Parkinson's Research
Ms. Jennifer Miller and Mr. Mark Ehret
Mr. Ira Millstein
Mr. Charles Moffett
Mr. and Mrs. Andy Moller
National Multiple Sclerosis Society
Mr. Michael O'Halleran
Mr. and Ms. William Osborn
Mrs. Janet Kelly Phillips
Margot and Thomas Pritzker
Family Foundation
Ms. Patricia Quick
Ms. Margaret Rice
Ms. Liz Robbins and Mr. Doug Johnson
Ms. Pilar Crespi Robert and Mr. Stephen Robert
Mr. and Mrs. Thomas Roberts
Mr. and Mrs. Elihu Rose
Ms. Emily Rose
Mr. and Mrs. Jack Rudin
Patrick G. and Shirley W. Ryan Foundation
Ms. Patricia Bennett Sagon
Mr. and Mrs. Richard E. Salomon
Mr. and Mrs. Gerald Schaeffer
Mr. and Mrs. George W. Schiele
The Sheldon H. Solow Foundation
South Coast Capital Corporation, Mr. Philip Lovett
Mrs. Edward D. Stone
Mr. and Mrs. Donald Tober
Mrs. Elizabeth van Merkensteijn
Trish and George Vradenburg, USAagainstAlzheimer’s
Mrs. Jeanette Sarkisian Wagner and Dr. Paul A. Wagner
Mr. and Mrs. John F. Walsh
Weil, Gotshal & Manges Foundation Inc.
Wheels, Inc.
Mrs. Malcolm Hewitt Wiener
The Honorable Corinne Wood and Mr. Paul Wood
Ms. Linda Zambelli
Mr. and Mrs. Carl Zelinsky
Mr. Mortimer B. Zuckerman

$1,000 to $4,999
Anonymous (3)
Mr. and Mrs. Frederick R. Adler
Ms. Susan Agger
Ms. Tina Alster
Mr. Ronald A. Altman
Mr. and Mrs. John Amboian
Mr. and Mrs. Steven Ames
Mr. Roger Anderson
Ms. Gloria Anderson
Mr. Richard Anseres
Mr. and Mrs. John Angelo
Mr. Artemis Anninos
Mr. Edgar Bachra
The David and Barbara Baldwin Foundation
Ms. Mercedes T. Bass
Mr. Dennis Basso and Mr. Michael Cominotto
Baxter Healthcare Corporation
Mr. Leonard J. Bencivenga
Dorothy G. Bender Foundation
Mr. and Mrs. Bruce Berger
Dr. Arnold Berman
The Honorable and Mrs. Stuart Bernstein
Bernstein Family Foundation
BioFocus
Mr. Steve Blacher
Mr. and Mrs. Wolf Blitzer
Mr. and Mrs. Bernard Bloom
Mr. and Mrs. Roy Bostock
Dr. and Mrs. Mark K. Bowen
Mrs. Susan Braddock
Mr. and Mrs. Lawrence Brandt
Dr. Eric Braverman
Mr. Daniel J. Brigati
Mr. and Mrs. Alan Bubes
Mrs. Melva Bucksbaum and Mr. Raymond Learsi
Mr. and Mrs. Leonard Burka
Ms. Sharon Burka
Ms. Bari Burman
Ms. Mary K. Bush
Mr. and Mrs. Louis Caceres
Mr. and Mrs. William Cafritz
Ms. Caitrine Callison
Mr. and Mrs. Charles Cangro
Ms. Giosetta Capriati
Mr. John K. Castle
Mr. and Mrs. Wright Caugman
Ms. Lois Chiles and Mr. Richard Gilder
Ms. Jeanne Coleman
Mr. and Mrs. Charles Collat, Sr.
Mr. and Mrs. Mark Colman
Mr. Owen Condon
Mr. and Mrs. Bob Cooney
Mr. and Mrs. John D. Cooney
Mr. and Ms. Peter H. Coors
Mrs. Joyce Cowin
Ms. Brittain B. Cudlip
Mr. and Mrs. Arnaud de Borchgrave
Mr. John D. Demsey
Mr. Paul Deslongchamps
Mr. Lawrence Doyle
Dr. and Mrs. Ronald Dozoretz
Mr. and Mrs. Rodman Drake
Mr. and Mrs. Kenneth Duberstein
Mr. and Mrs. Todd Eagle
Mr. and Mrs. John Eastman
Eckert Seamans Cherin & Mellott, LLC
Mr. and Mrs. Lewis M. Eisenberg
Mr. and Mrs. Richard Elden
Ambassador and Mrs. Edward E. Elson
Mrs. Sondra Berman Epstein and Mr. Sidney Epstein
Mr. and Mrs. Melvyn J. Estrin
Mr. Stuart M. Fain
Mr. and Mrs. William Farley
Ms. Samia Farouki
Mr. and Mrs. David C. Farrell
Mr. and Ms. W. J. Farrell
Mr. and Mrs. Kenneth Feld
Mr. and Mrs. Marshall Field
Mr. and Mrs. Harry Fields
Dr. Howard Fillilt
Ms. Marcia French
Mrs. Emily T. Frick
Ms. Charlotte Moss and
Mr. Barry Friedberg
Fross Zelnick Lehrman & Zissu P.C.
Ms. Mary Galvin
Gantz Family Foundation
Ms. Brooke Garber and
Mr. Daniel M. Neidich
Mr. and Ms. Robert P. Garrett
Mr. Bruce Gelb
Genentech USA
Mr. David Gerson
Mr. Andrew D. Gilbert
Ambassador and Mrs. Joseph B. Gildenhorn
Mr. and Mrs. Jim Glassman
Mr. Joseph B. Glossberg
Mr. David Goodes
Mr. Sheldon Gordon
Mr. and Mrs. Ian Graham
Mrs. and Mrs. Richard Gray
Mr. Peter Green
Ms. Sylvia Greenberg
Mr. Alexis Gregory
Mr. and Mrs. Philip M. Gross
Mr. and Mrs. Martin Gruss
Ms. Agnes Gund
The Geoffrey Gund Foundation
Hagin Capital LLC
Ms. Judy Jackson and Mr. Bruce Haims
Mr. and Mrs. William H. Hamm III
Ms. Jane Harman
Mr. Chris Harris
Ms. Ellen R. Harris
Mr. Kenneth H. Heitner
Mr. and Mrs. John Heller
Mr. and Mrs. David Heller
Mr. and Mrs. Barnett Helzberg, Jr.
Mr. Terrence Hendricks
Mr. and Mrs. Lawrence Herbert
Mrs. Ronnie F. Heyman
Mr. and Mrs. John Hickey, Jr.
Mr. John Higgins
Ms. Catherine Hirsch
Ms. Mellody L. Hobson
Ms. Ann Marie Huebner and
Mr. Ross P. Waller
Ms. Berna Huebner
Mr. and Mrs. Kit Illick
Ms. Deborah Imperatore
Mr. and Mrs. Verne G. Istock
The Melvin and Rosalind Jacobs
Family Foundation
Mr. and Mrs. Richard Jaffe
Ms. Nada Jain
Mr. David Jarvis
Mr. and Mrs. Maurice Jennings
Mr. Christopher Johnson
Jordan Industries International LLC
JSW Lifesciences GmbH
Lady Barbara Thomas Judge
Rita J. and Stanley H. Kaplan Family
Foundation, Inc.
Kasper
Mr. and Mrs. John Kelsey
Mr. and Mrs. James C. Kennedy
Mr. and Mrs. Shaker Khayatt
Dr. and Mrs. Israel Kogan
Mr. Paul Konstant
Mr. and Mrs. Frederick A. Krehbiel
Mr. and Mrs. H. Fred Krimendahl II
Mr. and Mrs. Peter Krulwich
Ms. Joan Krupskas and Mr. Ted Barbour
Ms. Elizabeth Szancer Kujawski and
Mr. Tom Zoufaly
Mr. Jeff Kurtz
Mr. and Mrs. Richard Landau
Ms. Marilyn Brody Lane
Ms. Claudine Larocque
The Honorable and Mrs. Ronald S. Lauder
Mr. William P. Lauder
Mr. and Mrs. Brian Lawlor
Ms. Ginger Layatham
Lazard Freres & Co. LLC
Ms. Alexandra Lebenthal and
Mr. Jeremy Diamond
Mr. and Mrs. Melvin Lenkin
Ms. Marcia Levine and Mr. Pierre Levai
Mr. and Mrs. Noel Levine
Mr. and Mrs. Steven Levy
Mr. and Mrs. Samuel H. Lindenbaum
Mrs. Anne H. Lindgren
The Meno Lissauer Foundation Inc.,
Ms. Alison McCall and Mr. Peter Elell
Mr. Leonard D. Litwin
Mr. and Mrs. Carl Lobell
Elizabeth and Jeff Louis Foundation
Mrs. Nancy Lynn
Mr. and Mrs. Harry Macklowe
Mr. and Mrs. Vincent A. Mai
The Honorable and Mrs. Frederic V. Malek
Mr. Mark Maltzman
Mr. and Mrs. James C. Marlas
Mr. and Mrs. Bennett Marshall
Jack C. Massey Foundation
Mr. and Mrs. Jonathan P. May
Ms. Katherine Mayer
Mrs. Shirley Maytag-King
Ms. Alison McCall and Mr. Peter Elell
Ms. Anya McComsey
Ms. Judy McLaren
Ms. Robin Meltzer
Mr. Gilles Mendel
Mr. and Mrs. Sam Michaels
Ms. Sandra Miele, The Hampshire
Companies
Mr. and Mrs. Donald K. Miller
Mr. and Mrs. James N. Mills
Mr. and Mrs. Andrew Mills
Ms. Karen Moran
Mr. Patrick R. Morris
Mr. and Mrs. Lucian Morrison III
Morgan Stanley
Mr. and Mrs. Allan Muchin
Mule Family Foundation
Mr. and Mrs. Mark R. Neaman
Ms. Judith E. Neisser
NeuroDetective International Inc.
Neurophage Pharmaceuticals, Inc.
Mr. and Mrs. Howard Newman
Mr. and Mrs. William A. Nitze
Ms. Virginia Norton
Mr. and Mrs. Larry Nussdorf
Mr. Jon Old
Ms. Hannah Pakula
Patheon
Ms. Darlene Pasquill and Mr. Mike Hiller
Dr. Steven Paul
Mr. and Mrs. Richard S. Pearman
Ms. Erica Peitler
Mr. and Mrs. John Pomerantz
Ms. Phoebe Farrow Port
PsychoGenics, Inc.
Ms. Deirdre Quinn
reMYND
Mr. Clayton Reynolds
Mr. and Mrs. Lewis Rice
Ms. Denise Rich
Richard Gray Gallery L.P.
Judith Ripka
Mrs. Sheila Johnson Robbins
Mrs. Anita Roselle
Mr. Joseph Rosenblatt
Ms. Nina Rosenwald
Mr. Ronald Rosner
Mr. and Mrs. Laurence Rosoff
Mrs. Janet C. Ross
Mr. and Mrs. Wilbur L. Ross, Jr.
Dr. and Mrs. Ronald M. Roth
Mr. and Mrs. Howard J. Rubenstein
The Shelley & Donald Rubin Foundation
In 2012, gifts were made to the ADDF in honor of the following individuals:

Milton Lewin and Milian Becker
Karen Weise and Noah Buhayar
Amy DiGeso
Emory University ADRC
Agnes Farrell
Howard Fillit
Ingrid Flores
Nancy Foxman
Rosemary Furman
Frances R. Gewirz
Melvin R. Goodes
Mary Alice Griffin
Ron Johnson
Leonard A. Lauder
Angel Lewis
Thelma “Bunny” Llyod
Rita Lullo
Nancy Lynn
Marilu Marshall
Lee Motler
Fred Myers
Malene Moore Nadeau
Dolly Reed
Phoebe Rice
Tom and Cece Ricketts
Pessie Sue Weir and Margaret Roberson
Rose Santoro
Mary Ellen Schaefer
Peter J. Solomon
B.G. Starnes
Dorothy Stein
Joan Sutton Straus
Mary Rose Taylor
Elsie Williams
Barbara Wolfson

Mrs. Genevieve McSweeney Ryan
Mr. Kevin M. Ryan
Mr. and Mrs. David Sable
Mr. and Mrs. Sal Salibello
Satori Pharmaceuticals Inc.
Mr. and Mrs. George Saunders, Jr.
Mr. Peter M. Scheer
Mr. and Mrs. Lloyd Schermer
Mr. David T. Schiff
Mr. and Mrs. Mitchell Schrage
Mrs. Barbara Schwartz
Mr. Edmondo Schwartz
Mr. and Mrs. Chris Segal
Ms. Pamela Seymour and Mr. Robert Schumer
The Susan Stein Shiva Foundation
The Carlynn and Lawrence Silverman Family Foundation Inc.
Mr. Thomas Slater
Mr. and Mrs. Joshua Slocum
Mr. and Mrs. Albert H. Small
Mr. and Mrs. Albert Small, Jr.
Mr. and Mrs. Joseph E. Smith
Ms. Angela Smith Domzal
Mr. and Mrs. Richard Solomon
Peter J. Solomon Company, LP
Mr. Maurice Sonnenberg
Ms. Lisa B. Spikell
Ms. Emily Spitzer
Mr. and Ms. Jeffrey Steinberg
Dr. Philip Stieg
Mr. and Mrs. David A. Stockman
Ms. Eleanor Sullivan
T. Rowe Price Foundation, Inc.
Ms. Andrea Taetle
Mr. and Mrs. A. Alfred Taubman
Ms. Laurie M. Tisch
Ms. Jamie Tisch
Ms. Lee Traub
Ms. Alexandra Trower and Mr. Jon Lindsey
Ms. Eunice C. Valdivia
Ms. Sahba Vaziri and Mr. Ali Reza
Viking Global Investors LP
Mr. and Mrs. Curt von Boetticher
Mr. and Mrs. Michael Voslow
Ms. Gretchen A. Wayne
Ms. Jane Greenwald and Mr. Lawrence A. Wein
The John L. & Sue Ann Weinberg Foundation
Mr. and Mrs. Walter Weiner
Ms. Linda Weinstein
Mr. and Mrs. Ronald Weintraub
Dr. Arthur C. Weissenseel
Mr. Mason Weiss
Dr. Tina West

The Honorable and Dr. Marcus Williams
Ms. Jan Willinger
Mr. and Mrs. Robert Zarnegin
Mr. and Mrs. Shelton Zuckerman

2012 In-Kind Donors
Abrielle Fine Linens & Lingerie
Amaryllis Flowers
Art of Giving
Bedford Post Inn
BLT Steak
Bobbi Brown
Bottega Veneta
Bumble & bumble.
Café Milano
Carolina Herrera
Clay & Co.
Colicchio & Sons
Colliers International NY LLC
Creative Parties, Ltd.
David Burke
Jay and Cindy DeFrancesco
Delta Airlines
Denihan Hospitality Group
Design Cuisine
Diener Jewelers – Allison Diener Perlmutter
DKNY
Douglas Hannant
Silvia and Peter Dreyfuss
Eckert Seamans Cherin & Mellott, LLC
The Estée Lauder Companies Inc.
Fairmont Hotels & Resorts
Fiola Restaurant
The Four Seasons Restaurant
Four Seasons Hotel, Washington, DC
Lenny Gordon
Gotham Dream Cars
HealthyChocolate NY
Hickey Freeman
Hu’s Shoes + Hu’s Wear
Jennifer Miller Jewelry
Jenny Ng Designs
JetBlue Airways
Johnny Brookheart Jewelers
Judith Lieber
Judith Ripka
Just Cakes
Kimpton Hotels & Restaurants
Knightsbridge Management Corporation
Elise and Marc Lefkowitz
Le Relais de Venise L’Entrecôte
Lincoln Financial Group
Marchesa
Martek Corporation

18
We are grateful to all who contributed to the ADDF in 2012.
For a complete list of donors, please visit www.AlzDiscovery.org

Corporate and Foundation Membership Circle
Alzheimer’s Foundation of America
The Association for Frontotemporal Degeneration
BrightFocus Foundation
Charles River Laboratories
Ernst & Young, LLP
The Estée Lauder Companies Inc.
First Republic Bank
Flexjet
Graff Diamonds
Le Papillon Ltd.
Lewy Body Dementia Association
Merck Research Laboratories
The Neiman Marcus Group
Northern Trust
Pfizer
Saks Fifth Avenue
Sotheby’s
Staples
Tommy Hilfiger Corporate Foundation
UBS

“The life given us by nature is short, but the memory of a life well spent is eternal.”
— Cicero

The ADDF remembers and honors those taken by Alzheimer’s in 2012 by continuing to fight for a cure.

Melba Bickham
Jean T. Brigati
Paul Connolly
Mary Louise Deal
Edwin Everitt
Beverly Harris
Irwin “Win” Hecht
Thomas Hendricks
Gloria Hirtz
Shirley Lichaw
Ronald Loeb
Lydia Melendez
Joan Morse
Bill Opelka
Connie Rice
Phyllis Rosenthal
Warren E. Siegmond

Legacy Giving

Charitable bequests to the ADDF help us to fulfill our mission to accelerate the discovery of drugs to prevent, treat and cure Alzheimer’s disease, related dementias and cognitive aging.

Simply use this suggested language in your will or living trust:
“I bequeath [dollar amount/percentage] to the Alzheimer’s Drug Discovery Foundation, a New York State not-for-profit organization.”

If you already have a will or living trust, you may add the ADDF as a beneficiary through a codicil or trust amendment. Bequests to the ADDF are not subject to estate tax. Consult with your attorney or other advisors to make sure that your bequest makes sense as part of your overall estate plan. For more information about ways to give, please call 212-901-8000.
ADDf 2012 Grants

Preclinical Drug Discovery Program — Academic

Carmela R. Abraham, PhD
Boston University School of Medicine, Boston, Massachusetts
Development of Klotho Enhancers as Novel Therapeutics for AD
AWARD: $196,421

Antonino Cattaneo, PhD
Scuola Normale Superiore, Pisa, Italy
Preclinical development of “painless” human Nerve Growth Factor
AWARD: $75,000

Marcie Glicksman, PhD
Harvard Neurodiscovery Center, Cambridge, Massachusetts
Collaborative CNS Screening Initiative
AWARD: $123,433
*Beyond Batten Disease Foundation/Multiple Sclerosis Society

Anil Gulati, MD, PhD
Midwestern University, Downers Grove, Illinois
Nanocarrier formulation of ETB receptor agonist, IRL-1620, for the treatment of Alzheimer’s disease
AWARD: $96,694

Andrew Horti, PhD
Johns Hopkins University, School of Medicine, Baltimore, Maryland
Cannabinoid CB2 radioligands for PET imaging of neuroinflammation in Alzheimer’s disease
AWARD: $149,970

Li Huang, PhD
Duke University, Durham, North Carolina
Proteasome activator as drug candidates in Alzheimer’s disease
AWARD: $100,000
*Alzheimer’s Drug Discovery/Alzheimer’s Foundation of America Award to Accelerate Drug Discovery

Jeff Kuret, PhD
Ohio State University, Columbus, Ohio
Imaging agents for diagnosis of tauopathic neurodegenerative diseases
AWARD: $150,000
*Alzheimer’s Drug Discovery Foundation/Alzheimer’s Foundation of America Award toAccelerate Drug Discovery

Ana Martinez, PhD
Medicinal Chemistry Institute-CSIC, Madrid, Spain
Evaluation of cognition and hippocampal neurogenesis after oral administration of a phosphodiesterase 7 inhibitor in an Alzheimer’s disease mice model
AWARD: $120,000
Elliot Mufson, PhD  
Rush University Medical Center, Chicago, Illinois  
**CSF proNGF: a putative biomarker for Alzheimer's disease**  
**AWARD:** $130,734

John Schetz, PhD  
University of North Texas Health Science Center, Fort Worth, Texas  
**Target-based discovery of druggable regulators of peroxynitrite-induced nitration as a novel treatment strategy for Alzheimer's disease**  
**AWARD:** $199,803

Eugenia Trushina, PhD  
Mayo Clinic Rochester, Rochester, Minnesota  
**Mechanism of restoration of mitochondrial function by tricyclic pyrone compounds**  
**AWARD:** $181,757

Neil Vasdev, PhD  
Massachusetts General Hospital/Harvard Medical School, Charlestown, Massachusetts  
**Radiopharmaceutical Development for Imaging Metabotropic Glutamate Subtype 5 Receptors (mGluR5) in AD patients with PET**  
**AWARD:** $175,000

Yan Zhang, PhD  
The University of Texas at Austin, Austin, Texas  
**Selective Inactivation of Human Phosphatases for Neuronal Regeneration**  
**AWARD:** $132,960

**Biotechnology Program — Preclinical**

Joseph Harding, PhD  
M3 Biotechnology, Inc., Pullman, Washington  
**Development of small molecule hepatocyte growth factor mimetic for the treatment of dementia**  
**AWARD:** $174,993

Mark Rampy, PhD  
CohBar, Inc., Pacific Palisades, California  
**Optimization and Preclinical Development of a Novel Therapeutic Peptide For Alzheimer’s Disease**  
**AWARD:** $205,260

Thadd Reeder, PhD  
Glialogix, Inc., San Francisco, California  
**Testing of GLX1112 in an Alzheimer’s mouse model**  
**AWARD:** $207,000

Lawrence Wennogle, PhD  
**Validation of a Novel Target Mechanism to Counter Progression of Alzheimer’s Disease**  
**AWARD:** $219,667

**Program to Accelerate Clinical Trials (PACT)**

Sandra Black, MD, FRCP(C)^  
Sunnybrook Research Institute, University of Toronto, Toronto, Canada  
**Sartans to Slow Alzheimer's Disease: A Randomized, Open-Label, Head-to-Head, Proof-of-Concept Study of Angiotensin Receptor Blockers Versus ACE Inhibitors in Hypertensive Mild-Moderate AD Patients using Ventricular Enlargement as Primary Outcome**  
**AWARD:** $992,388  
*The W. Garfield Weston Foundation/Alzheimer’s Drug Discovery Foundation of Canada Award*

Steven Estus, PhD  
University of Kentucky Research Foundation, Lexington, Kentucky  
**Translating genetics into biomarkers and therapies: apoE/Ab and apoJ/Ab complex levels and lipidation state as AD biomarkers modulated by VPA**  
**AWARD:** $117,000

Allan Levey, MD, PhD  
Emory University School of Medicine, Atlanta, Georgia  
**A phase IIa, double-blind, placebo-controlled, biomarker study of atomoxetine in subjects with mild cognitive impairment**  
**AWARD:** $447,900  
*2012 Fund a Scientist Auction Award*

Olga Meuldenbroek, PhD  
Radboud University Medical Centre, Nijmegen, The Netherlands  
**Nilvad add-on study: The effects of nilvadipine on blood pressure, cerebral autoregulation, blood flow and damage in Alzheimer’s disease**  
**AWARD:** $380,224

Ana Pereira, MD  
The Rockefeller University, New York, New York  
**Glutamatergic Dysfunction in Cognitive Aging: Riluzole in Mild Cognitive Impairment**  
**AWARD:** $250,000

**Biotechnology**

Gary Landreth, PhD  
ReXceptor Therapeutics, Cleveland, Ohio  
**A Randomized Controlled Study to Evaluate the Effect of Bexarotene, an RXR Agonist, on beta-Amyloid and Apolipoprotein E Metabolism in Healthy Subjects**  
**AWARD:** $750,000  
*The Charles Evans Foundation/Alzheimer’s Drug Discovery Award; BrightFocus Foundation*

For more information about the ADDF, please visit [www.AlzDiscovery.org](http://www.AlzDiscovery.org)
ADD-F-Belfer ApoE Therapeutics Innovation Program

Mary Jo LaDu, PhD
University of Illinois at Chicago, Chicago, Illinois
Modulation of human apoE isoform levels as a therapeutic target using a new Alzheimer’s disease transgenic mouse model
AWARD: $91,000
*Alzheimer’s Drug Discovery Foundation/The Samuel Freeman Charitable Trust Award to Accelerate Drug Discovery

Cheryl Wellington, PhD
University of British Columbia Hospital, Vancouver, Canada
Novel modulators of apoE function
Award: $148,000

Biotechnology
Rick Jack, PhD
Madera Biosciences, Inc., San Diego, California
In vitro and in vivo optimization of ApoE modulators for Alzheimer’s disease
AWARD: $298,500

ADD-F-Charles River Aging Partnership Program

Khalid Iqbal, PhD
New York State Institute for Basic Research in Developmental Disabilities, New York, New York
Rescue of Neuronal Plasticity and Cognitive Impairments in Aged Rats
AWARD: $254,450

ADD-F-Association for Frontotemporal Degeneration Partnership Program

Nigel Cairns, PhD
Washington University, St. Louis, Missouri
Restoring progranulin in frontotemporal disease
AWARD: $156,990

Jeffrey Rothstein, MD, PhD
Johns Hopkins University, School of Medicine, Baltimore, Maryland
Development of Antisense therapy and Therapeutic biomarker for C9orf72 FTD/ALS mutation patients
AWARD: $125,856

W. Haung Yu, PhD
Columbia University Medical Center, New York, New York
Development of small molecule enhancers of autophagy for the clearance of protein aggregates and treatment of FTD
AWARD: $149,642

ADD-F-Lewy Body Dementia Association Partnership Program

Omar El-Agnaf, PhD
United Arab Emirates University, Al-Ain, United Arab Emirates
Testing a combination of CSF biomarkers for discriminating dementia with Lewy bodies from other neurodegenerative disorders and controls
AWARD: $100,000

Michelle Mielke, PhD
Mayo Clinic Rochester, Rochester, Minnesota
Plasma lipidomic and alpha-synuclein comparison of individuals with alpha-synuclein, amyloid, or normal pathology
AWARD: $100,000

ADD-F-New York Academy of Sciences Partnership Program

Douglas Galasko, MD
University of California, San Diego, La Jolla, California
Development of synaptic biomarkers related to AMPA-receptor trafficking in Alzheimer’s Disease
AWARD: $140,000

Conference Grants

Jennifer Henry, PhD
New York Academy of Sciences, New York, New York
Targeting the Vasculature in Alzheimer’s Disease and Vascular Cognitive Impairment
AWARD: $16,719

Sharon Hesterlee, PhD
Association for Frontotemporal Degeneration, Philadelphia, Pennsylvania
Clinical Development in Frontotemporal Degeneration
AWARD: $5,000

George Vradenburg
USA Against Alzheimer’s Network, Washington, DC
AWARD: $10,000

David Woodland, PhD
Keystone Symposia on Molecular and Cellular Biology, Silverthorne, Colorado
New Frontiers in Neurodegenerative Disease Research
AWARD: $2,500
Alzheimer’s Drug Discovery Foundation

Statements of Financial Position

Assets

Cash and cash equivalents
  Operating $2,556,159
  Restricted 182,896
  Total cash and cash equivalents 2,739,055
Investment, at fair value 8,115,777
Contributions receivable 2,742,129
Other assets 16,224
Total assets $13,613,185

Liabilities and Net Assets

Liabilities
  Accounts payable and accrued liabilities $62,806
  Grants payable 7,485,431
  Deferred revenue 132,049
  Due to the Institute for the Study of Aging, Inc. 9,763
  Total liabilities 7,690,049

Net assets
  Unrestricted 4,920,240
  Temporarily restricted 1,002,896
  Total net assets 5,923,136

Total liabilities and net assets $13,613,185

Statement of Activities

Change In Net Assets

Support and Revenues
  Contributions and grants $5,930,926
  In-kind contributions from the Institute for the Study of Aging, Inc. 2,753,087
  Proceeds from special events, net of direct expenses 3,349,090
  Revenues
    Grant Returns 133,860
    Conference registration fees and other income 220,582
    Interest income 6,352
  Total support and revenues 12,393,897

Expenses
  Program services 8,004,920
  Fund raising 1,051,466
  Management and general 532,910
  Total expenses 9,589,296

Change in net assets 2,804,601
Net assets, beginning of year 3,118,535
Net assets, end of period $5,923,136

Audited financials available upon request

For more information about the ADDF, please visit www.AlzDiscovery.org
ADDF 2012 Board

2012 Board of Governors

Honorary Chairman
Sandra Day O'Connor

Co-Chairmen
Leonard A. Lauder
Ronald S. Lauder

President
Nancy Corzine

Robert A. Belfer
Bonnie Pfeifer Evans
Lady Lynn Forester de Rothschild
Melvin R. Goodes
Nancy Goodes
Randal Sandler
Alice Shure
Peter J. Solomon
Sally Susman
Paula Zahn

Ex Officio
Howard Fillit, MD
Nancy Lynn

Officers
Lisa Somar
Joan Krupskas

2012 Board of Overseers

Co-Chairmen
Susan Roth Katzke
Sharon T. Sager, CIMA
Randal Sandler

Carol Seabrook Boulanger
Charles Cangro
Faith Perlmutter Diamond
Julie Eskay-Eagle
Allan Green, MD, PhD, JD
Christopher Johnson
Alexandra Lebenthal
Elise Lebenthal Lefkowitz
Philip Lovett
Emilio Matt
Phebe Farrow Port
Joan Sutton Straus
Mary Rose Taylor
Alison Zaino
Linda S. Zambelli

Joint Annual Board Meeting of the Board of Governors and the Board of Overseers.
December 12, 2012

As of December 31, 2012

For more information about the ADDF, please visit www.AlzDiscovery.org
ADDF 2012 Staff

Howard Fillit, MD
Executive Director and Chief Science Officer

Diana Shineman, PhD
Director, Scientific Affairs

Rachel Lane, PhD
Assistant Director, Scientific Affairs

Penny Dacks, PhD
Assistant Director, Aging and Alzheimer’s Disease Prevention

Filomena Machleder
Assistant Director, Institutional Partnerships

Niyati Thakker
Grants Manager

Sara Classen
Coordinator, Conferences and Meetings

Natalie Romatz
Coordinator, Conferences and Meetings

Nancy Lynn
Executive Director and Chief Operating Officer

Vina Orden
Director, Major Gifts

Jayme Rubright
Director, Corporate and Strategic Relations

Kate Polidori
Assistant Director, Special Events

Allison Sawczyn
Assistant Director, Development

Carrie Tracy
Assistant Director, Special Events

Dina Miller
Development Associate

Elizabeth Feskoe
Coordinator, Database and Development

Mollie Wein
Special Events Coordinator

Finance

Ethan Hutchinson
Director, Finance and Administration

Diane Duong
Finance Manager

As of December 31, 2012
The ADDF has granted nearly $60 million to fund over 400 programs in 18 countries.